Opportunities and Challenges of Swarm AI for Decentralized Clinical Research

Swarm learning opens new opportunities for collaboration and innovation in clinical research where all members of the swarm have equal rights. Only algorithms and parameters are shared – with no central authority. Swarm creates many new opportunities in clinical research to develop new therapeutics,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blockchain in healthcare today 2022-07, Vol.5
Hauptverfasser: Maria Palombini, Director, Healthcare and Life Sciences Practice, IEEE SA, Prof. Dr. Joachim L. Schultze, Director Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Director, Genomics & Immunoregulation, LIMES-Institute, University of Bonn Germany, Krishnaprasad Shastry, Director, Distinguished Technologist, Hewlett Packard Enterprise (HPE), Vikram Shetty, Medical Director, Singapore and Asia Area Lung Cancer Lead, AstraZeneca
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Swarm learning opens new opportunities for collaboration and innovation in clinical research where all members of the swarm have equal rights. Only algorithms and parameters are shared – with no central authority. Swarm creates many new opportunities in clinical research to develop new therapeutics, epidemiology, genetics research and more. This session will unlock swarm principals, challenges and opportunities in clinical R&D driving wider adoption of its application(s) in the health domain. Key learnings will include: • Understanding the differences between federated machine vs swarm learning • The technical, policy and application barriers when it relates to transferring significant amounts of data • The steps and frameworks needed to drive wider understanding and adoption of the technology in clinical R&D • The pharma perspective: where does Swarm AI offer new solutions yet to be introduced to the drug development process
ISSN:2573-8240
2573-8240
DOI:10.30953/bhty.v5.212